Healthcare
Tango Therapeutics, Inc.(TNGX)
Live Price
Offline$27.97
-13.38% today
1Y Change
+506.95%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $2.44B
- Revenue Growth
- +48.3%
- EPS Growth
- +26.9%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tango Therapeutics, Inc. (TNGX) is a Healthcare stock with a market cap of $2.44B and listed on NASDAQ. The stock last traded around $27.97 and up 507.0% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +48.3%, EPS growth of +26.9%, a dividend yield of 0.0%. What stands out right now is revenue +48.3%, EPS +26.9%, free cash flow -5.8% with operating margin -178.4% and ROIC -29.3%. Valuation already assumes a fairly strong business story at price/sales 39.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TNGX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+48.3% vs +7.6% peer median
Operating Margin
Below sector median
-178.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +48.3% and EPS at +26.9%, with operating margin around -178.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.9% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | +0.1% | -12.1% | +34.4% |
2026 Mar 5, 2026 | +6.5% | +0.7% | +1.9% | +28.5% |
2025 Nov 4, 2025 | +1200.0% | -6.2% | +4.6% | +19.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TNGX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TNGX Max Drawdown
-29.24%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TNGX and SPY.
Company Overview
Tango Therapeutics, Inc.
NASDAQ Global Market
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
- Leadership
- Malte Peters
- IPO Date
- Sep 3, 2020
- Employees
- 155
- Street Address
- 100 Binney Street
- Mailing
- Boston, MA, 02142
- Region
- Boston, MA, US
- Reporting Currency
- USD
- Investor Line
- 857 320 4900
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 39.1
- Price/Book
- 7.0
Growth
- Revenue
- +48.3%
- EPS
- +26.9%
- Free Cash Flow
- -5.8%
Profitability
- Gross Margin
- 97.3%
- Operating Margin
- -178.4%
- Net Margin
- -162.9%
- ROE
- -50.3%
- ROIC
- -29.3%
Balance Sheet
- Debt/Equity
- 0.10
- Current Ratio
- 16.32
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.